Estudo de coorte retrospectivo | Em pacientes com tromboembolismo venoso (TEV), o tratamento com apixabam foi associado com menores taxas de TVE recorrente e sangramento em comparação ao rivaroxabam.

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine

Comentários:

Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology